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Abstract
Pin1 is an enzyme essential to cell cycle regulation and has a key role in 
cancer proliferation. This thesis reports ongoing efforts to obtain a Pin1 inhibitor 
exhibiting an inhibition constant in the nanomolar range.
It was previously found that Pin 1 activity could be inhibited using a short 
proline containing peptide sequence which also contains a stereospecific (3- 
substituted a-amino acid. Several proline analogues were tested for greater 
inhibition against Pin1 than previously synthesized Cbz-/_-Glu((3-phos)-Pro-NH2. 
It was found that using full length Pin1 in the chymotrypsin-coupled photometric 
assay rendered different values than using only the catalytic PPIase domain for 
Cbz-Z_-Glu((3-phos)-Pro-NH2, Kj = 54.1+1.8 pM and 20 ± 0.9 pM respectively. 
The potential effectiveness of the synthesized inhibitors against Pin1 was 
assessed using the same convenient chymotrypsin-coupled photometric assay 
against full length Pin1.
This thesis describes the synthesis of two novel compounds which 
exhibited an increase in inhibition relative to Cbz-/_-Glu((3-phos)-Pro-NH2 (Kj = 
54.1+1.8 pM) with results in the micromolar range; Cbz-Z_-Glu(f3-phos)-Pip-NH2 (Kj = 45.4+1.1 pM) and Cbz-/_-Glu(p-phos)-Methylpiperazine (Kj = 22.7+1.4 pM).
Keywords: Pin1, OBO ester, Pin 1 inhibition, ß-substituted glutamic acid, 
Chymotrypsin coupled kinetic assay.
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1.1 Peptidyl-Prolyl cis-trans Isomerase (PPIase) Activity
Proteins are a sequence of amino acids linked together in series through 
amide or peptide, bonds. Due to the partial double bond properties in the amide 
bond there are two conformations available in each peptide bond called cis and 
trans. Cis and trans can be defined as the dihedral angle, oo, between 
neighbouring a-carbons with an angle of 180° for trans and 0° for cis (see Figure 
1.1). The trans conformation of a peptide bond is favoured over the cis 
conformation in nearly all naturally occurring peptide bonds. This is due to 
increased conformational strain experienced in the cis conformation through 
steric hindrance. The steric hindrance experienced is between neighbouring a- 
carbon substituents, both the residue side chain as well as the carbonyl group. 
However, in a proline containing peptide bond, where proline is on the nitrogen 
side of the bond, both the cis and trans conformations are closer in terms of 
steric hindrance due to the higher substitution on the amide nitrogen (Figure 1.1). 
With the higher substitution on the nitrogen, the propensity for the trans isomer is 
reduced from 1000:1, in a non-proline containing peptide bond, to approximately 
3:1, with proline on the nitrogen side of the peptide bond. Thus, both isomers are 
naturally found in biological conditions.
Peptidyl-prolyl cis-trans isomerase (PPIase) activity catalyzes the 
relatively slow cis-trans isomerization of the prolyl-amide bond. PPIase activity 
affects protein regulation, folding, and biological activity of many target proteins
l
[1-4]. PPIase activity is ubiquitously found in both prokaryotic and eukaryotic 
organisms. There are three families of proteins which posses PPIase activity; the 
FK506 binding proteins (FKBPs), the cyclophilins (CyPs), and the parvulin family 
of proteins.
Figure 1.1 Visual representation of A) non-proline containing peptide bond in trans and 
cis conformations and B) proline containing peptide bond in trans and cis conformations.
The CyPs and FKBPs, which are also known as immunophilins, possess 
immunosuppressant activity [5] and bind to the immunosuppressant drugs 
cyclosporin A (CsA) and FK506 respectively, from which they derive their names 
[6], However, the PPIase functionality of the immunophilins is not necessary for 
their immunosuppressive effects. It is the topology of the protein-drug complex 
which affects immunosuppressant activity. Upon binding to the respective 
immunosuppressant drug, the topology of the protein changes which then 
interferes with the transduction pathway blocking T-cell activation [2, 6]. CyPs 
and FKBPs have been shown to influence the folding of several proteins such as2
collagen [7-9], carbonic anhydrase [10, 11], chymotrypsin inhibitor [12], and 
ribonuclease [13]. However, there is no definitive evidence that the PPIase 
activity of both the CyPs and FKBPs is essential in vivo.
PPiC (peptidyl-prolyl cis-trans isomerase), isolated from E. coli, was the 
first of the parvulin family to be categorized [14, 15]. The human homologue Pin1, 
Peptidylprolyl cis/trans Isomerase, NIMA-interacting 1, was later discovered 
through a yeast two-hybrid screen designed to locate proteins which interact with 
Never in Mitosis Gene A (NIMA) [16].
1.2 Pin1
The enzyme Pin1 has been implicated in cell cycle control [17, 18], 
cytokine production [19-21], neurodegenerative disorders [22, 23], Human 
Immunodeficiency Virus (HIV) proliferation [24], and tumourgenesis [25] making it 
an attractive target for research.
1.2.1 Structure, Domains, and Recognition Motif of Pin1
Whereas Pin4/Par14 found in mice, consists only of a PPIase domain, 
Human Pin 1 is composed of two domains, the tryptophan rich WW domain on 
the N-terminus (residues 1-39) and the C-terminal catalytic PPIase domain 
(residues 45-163) [16, 26],
The WW domain binds to proline rich or proline containing regions of 
proteins/peptides [27]. The WW domain of Pin 1 is classified as a Group IV 
protein-protein interaction domain which binds to pSer/pThr proline ligands [27].
3
The small domain is an anti-parallel (3-sheet consisting of three strands 
connected in series with short loop regions. Interestingly, the WW domain family 
is the smallest protein domain classified that does not require any ligands, 
disulphide bonds, or cofactors to remain stable [28], Furthermore, the WW 
domain has been shown to act as a recruiting domain, allowing interaction 
partners to bind as well as bring substrates close to enzymes [29].
The larger PPIase domain also interacts with proline containing 
sequences, specifically with ligands containing pSer/pThr-proline. The PPIase 
domain consists of a (3-sheet of four strands arranged in an anti-parallel fashion 
forming a beta roll in the center of the domain, one 3/10 helix, and three a- 
helices. Helices 1-3 (a-helix 1 and 2 as well as the 3/10 helix) are arranged 
around the central sheet on the convex side of the roll. However, helix 4 (a-helix 
3) is arranged on the concave side of the roll effectively closing the gap one on 
side of the roll. The active site on the domain is located on the open side of the 
roll. The PPIase domain is highly conserved in the parvulin family among most 
species [30].
Currently there is conflicting evidence on the overall structural 
arrangement of the protein domains. NMR data suggests that the WW domain 
and the PPIase domain remain loosely arranged, whereas crystal structure data 
promotes close interaction between the WW and PPIase domains [31, 32]. 
Figure 1.2 depicts both NMR and crystal structures of Pin1.
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A)
Figure 1.2 The PPIase domain, denoted by hollow arrows, are in approximately the 
same orientation to demonstrate the high degree of freedom of movement of the W W  
domain, denoted by solid arrows. A) Crystal structure, pdb code 2ZQS, of Pin1 mutant 
C113A [31] B) NMR structure, pdb code 1NMV, of Pin1 [32].
1.2.2 Pin1 PPIase Mechanism
The mechanism of Pin1 activity is not fully understood, however, it is 
known that Pin1 does not make or break a bond [33]. The rotation of solely the 
prolyl-amide bond, while maintaining the conformation of all other bonds, is 
considered a highly unfavourable mechanism. For the rotation of only the prolyl- 
amide bond a large shift in the ligand’s structure would have to occur. This would 
require a large amount of free energy in the transition state. This mechanism of 
action may be possible for smaller peptide structures; however, this could lead to 
an unfavourable loss of binding energy in the complex. The rotation of the prolyl
5
peptide bond could also be accomplished by the rotation of several other 
adjacent bonds to achieve an overall pSer/pThr-Pro isomerization [34]. 
Furthermore, it is possible that the rotation of other bonds could be “pre­
determined” in target proteins and act in the signaling mechanism of the target 
protein [34].
1.2.3 Pin1 Interaction Partners and Disease States
The action of Pin 1 ultimately alters the stability, functionality, and/or final 
cellular location of the target molecules. This has a downstream effect in the 
biological pathways the target molecules belong to [4]. To name a few, 
interactions with NIMA [16], Cyclin D1 [18], Cdc25 phosphatase [35], 
phosphorylated Myt1 [35], PLK1 [36], p73 [37], p53 [38], phosphorylated tau 
protein [39, 40], and CK2 [41] have been identified for Pin 1. All of these Pin1 
interactions occur in a phosporylation dependant manner [4, 40, 42], Pin1 has 
also been shown to interact with transcription factors such as RNA Polymerase II 
(RNAP2) [4]. Clearly, Pin1 has an important role in cell regulation and function.
1.3 Pin1 in Cell Cycle Regulation and Cancer
NIMA is a mitotic kinase in Asperillus nidulans where overexpression 
induces premature chromosome condensation followed by apoptosis. However, if 
Pin 1 is also overexpressed there is a prevention of the premature chromosome 
condensation. It was also shown that the overexpression of just Pin1 leads to the 
inhibition of transition into mitosis causing G2 arrest [16], In this case G2 arrest is
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caused by the inactivation of cell division cycle 2 (CDC2) and Cyclin B [42], Low 
Pin 1 levels have been shown to cause an increase in abnormal G2 to M 
transitions [17]. In this regard, Pin1 could potentially act as a molecular timer for 
the cell cycle.
However, Pin1 has been found to be up-regulated in several cancers 
including prostate, ovarian, and breast [43]. It is possible that up-regulation or 
overexpression of Pin 1 can lead to uncontrolled abhorrent cell proliferation 
causing cancer.
Thus, there is evidence that Pin1 acts as a protector against oncogenic 
transformations, as well as has a tumourigenic effect. It is clear that Pin1 has a 
complex involvement in cell cycle regulation.
1.4 Pin1 and Alzheimer’s Disease
Pin 1 has been shown to regulate the phosphorylated state of both Tau 
and amyloid precursor protein (APP) through cis/trans isomerization [23, 40]. 
Loss of Pin 1 function has shown an age dependent relationship for Tau and 
related pathologies in mice. It has also been revealed that neural tissue of 
Alzheimer’s disease patients have a significantly lower amount of functional Pin1 
[39]. In the absence of Pin1, A(342 is formed which leads to plaque formation 
whereas in the presence of Pin1 the supposedly benign a-APP is formed [40]. 
Thus, it can be concluded that Pin 1 acts to guard neural tissue from plaque 
formation.
7
Interestingly, it was shown through a longitudinal study that there is an 
inverse correlation between Alzheimer’s disease and cancer in patients [44], The 
development of one disease seems to inhibit the development of the other. Pin1 
expression and activity has been implicated in these findings.
1.5 HIV
The human cytosine deaminase APOBEC3G (A3G) restricts the 
incorporation and replication of Human Immunodeficiency Virus (HIV) virions in 
human cells [45], In vivo assays indicate that cells containing a reduced activity 
Pin1 mutant and wild type A3G have stronger resistance to HIV. However, cells 
with wild type Pin 1 and wild type A3G have a higher incorporation rate of HIV 
[24]. Cells containing no A3G were found to have the highest infection rate. Thus, 
it can be concluded that Pin 1 activity is influential in HIV infection rate. The study 
also concluded that wild type Pin1 has a strong interaction with A3G, while the 
W34A Pin1 mutant has minimal interaction with A3G, providing evidence that the 
interaction is not non-specific.
Interestingly, HIV-1 contains the genetic code for an accessory protein, Vif, 
which is thought to increase the phosphorylation at Ser16 on Pin1. Pin1 is not 
overexpressed in Vif mediated phosporylation control but it would appear that the 
activity of pSer16 Pin 1 has been increased [24]. The mechanism for the 




As mentioned, Pin1 has an intricate and not fully understood role in 
several different cellular functions. The ability for researchers to control the 
function of Pin1 could lead to break-through developments in cancer, Alzheimer’s 
disease, and potentially HIV research. Research into Pin1 inhibition began with 
the discovery that juglone, 5-hydroxy-1,4-naphthalenedione, derived from the 
black walnut (Juglans nigra) tree, was an irreversible inhibitor of Pin 1 [46]. 
Unfortunately, juglone has been shown to be too toxic, making it a poor 
pharmaceutical agent [47],
The majority of the synthetic inhibitors for Pin1 are peptide sequences which 
contain a proline analogue such as pipecolic acid (pip) [48-51] and/or other 
hydrophobic, non-proteinaceous amino acids, such as naphthylalanine (NAL) 
[50, 51] and 3-benzothienyl alanine (Bth) [50], many with Ki values in the nM-pM 
range. These peptide chain style of inhibitors contain residues which are rnot part 
of the recognition sequence of Pin1. The residues outside the binding picket are 
free to interact with accessory binding pockets on the proteins surface near the 
active site, thus increasing affinity. Table 1.1 demonstrates the sequences of a 
select few peptide chain inhibitors.
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Ac-Ala-Ala-(D)-Ser(P03H2)-Pro-Leu-pNA IC50 = 1.0 pM [52] 
Ac-Ala-Ala-(D)-Ser(P03H2)-Pro-Arg-pNA IC50 = 3.6 pM [52] 
Ac-Ala-Ala-(D)-Ser-Pro-Leu-pNA IC50 = 85 pM [52] 
cyclo(Arg-Arg-Arg-D-pThr-Pip-Nal-Arg-Arg-Gln) IC5o =1.1 pM [53] 
cyclo(D-Ala-lle-D-pSer-Pro-Nal-Orn-Gln) IC50 = 1.1 pM [53] 
cyclo(D-Arg-D-Arg-D-pThr-Pip-Nal-Arg-Gln) IC50 = 0.22 pM [53] 
cyclo(Cys-Arg-Tyr-Pro-Glu-Val-Glu-lle-Cys) Kj = 0.5 pM [54] 
Ac-Phe-D-Thr(P03H2)-Pip-Nal-Gln-NH2 Kj = 20.4 nM [51] 
Ac-Bth-Thr(P03H2)-Pip-Nal-Gln-NH2 Ki = 258 nM [50] 
Ac-Lys(A/-biotinoyl)-Ala-Ala-Phe-D-Thr(P03H2)-Pip-Nal-Gln-NH2 Kj = 4.8 nM [50]
Table 1.1 Peptide sequences of select peptide inhibitors.
Other compounds have also been designed as potential Pin1 inhibitors. 
Different experimental approaches have been attempted such as testing different 
ring structures [48], creating conformationally locked substrate mimics [55], and 
synthesizing juglone-like molecules [56]. Figure 1.3 shows a selection of Pin1 





K, = 18 [1M [48] Kj = 0.8 |iM [49]





IC50 = 1.5 |iM [56] IC50= 1.3 pM [55]
Figure 1.3 Selection of Pin 1 inhibitors.
An attempt to increase the inhibiting potential of the dipeptide pSer-Pro 
was explored previously by Laio and Lajoie (unpublished) through addition to the 
serine (3-carbon. Laio and Lajoie tested the effectiveness of different 
diastereomeric configurations of non-proteinaceous substitutions of ethyl, phenyl 
and acetyl groups on the serine (3-carbon. The substitutions were then evaluated 
for Pin1 inhibition. The addition of an acetyl group in the 2S, 3R configuration, 
Cbz-Glu((3-phos)-Pro-NH2 (Figure 1.4), proved to have the best inhibiting ability (Kj = 20.0+0.9 pM). From these studies it was postulated that the (3-carboxy 
group binds to the arginine on the surface of Pin 1. This is based on modeling the 
inhibitor with the crystal structure complex bound to a peptide inhibitor [51]. Using
l i
the same crystal structure it was seen that there is potential for additional binding 
in and around the proline binding pocket.
Figure 1.4 Structural representation of Cbz-Glu(p-phos)-Pro-NH2
1.7 Stereoselective Synthesis of p-substituted Serine Analogues
A unique method for synthesis a of p-aldehyde serine analogue was 
developed by Blaskovich and Lajoie in 1993 [57] and a full synthesis of Cbz- 
Glu(p-phos)-Pro-NH2 using the p-aldehyde strategy was completed by Laio and 
Lajoie in 2008 (unpublished). The method utilizes the 4-methyl-2,6,7- 
trioxabicyclo[2.2.2]octane ester (OBO ester) to retain the functionality of the 
carboxylic acid, to protect the chirality at the a-carbon as, well as to direct the 
addition at the p-carbonyl. The orthoester is added to Cbz N-protected serine 
through the esterification, and subsequent rearrangement, of oxetane to the 
carboxylic acid. The OBO ester significantly reduces the acidity of the a-proton 
which in turn reduces the propensity of enolization in the presence of the p- 
aldehyde, thus helping to maintain the chiral integrity of the a-carbon. The bulky
12
OBO ester also has the ability to direct stereoselective addition to the p-aldehyde 
in subsequent reactions. To synthesize Cbz-Glu(P-phos)-Pro-NH2, the 
Reformatsky addition was used to add a t-butyl protected acetate group to the 13- 
carbon. The OBO ester was selectively removed and the resulting free acid was 
coupled to proline using solid phase peptide synthesis and phosphorylated using 
dibenzyl- N, N- diisopropylphosphoramidite. The full synthetic strategy used by 








1.8 Stereoselective Addition to Carbonyl Groups
The process of addition to carbonyl groups to form enantiomerically 
enriched compounds can be explained through three major models. Classically, 
Cram’s rule [58] was applied in the formulation of stereospecific additions. 
Cram’s rule states that the largest group on the (3-carbon to the aldehyde will 
align parallel to the carbonyl if viewed using a Newman projection. This high 
energy state was thought to stress the molecule thus increasing reactivity. The 
prediction of the major product is such that the addition to the carbonyl will occur 
with a higher frequency from the less hindered face, see Figure 1.5.
Major Product
Figure 1.5 Major product prediction using Cram’s rule. Where L is a large substituent, 
M is a medium sized substituent and S is a small substituent such as hydrogen.
However, there was some experimental evidence that contradicted Cram’s 
rule which lead to the development of the Felkin-Anh model [59]. The Felkin-Anh 
model proposes that the largest R group on the carbon adjacent to the carbonyl 
be perpendicular to the carbonyl a bond and parallel to the tr bond orbital. The
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Burgi-Dunitz angle of attack would need to be satisfied for addition, and thus the 
least hindered attacking angle is the preferred addition face (Figure 1.6).
Figure 1.6 Major product prediction using the Felkin-Anh model. Where L is a large 
substituent, M is a medium sized substituent and S is a small substituent such as 
hydrogen.
An alternative way to predict the addition to a carbonyl group is through 
chelation control. A soluble coordinating metal ion, such as Zn2+, is able to 
coordinate with the carbonyl and adjacent functional groups which are electron 
rich. Depending on the existing configuration of the molecule the coordinating 
ion will “hold” a target molecule in position to expose either the re or si face to the 
nucleophile. The major product from 1, 2 or 1, 3 chelation control is completely
16
dependent on the existing stereochemistry, the existence of an electron donor 
group, and the use of a coordinating metal ion (Figure 1.7)
Less hindered More hindered
Figure 1.7 Major product prediction using 1, 2 chelation controlled addition. Where L is 
a large substituent and S is a small substituent such as hydrogen.
The Felkin-Anh model and Cram’s rule do not always render the same 
major product. The use of a less coordinating metal will reduce the effects of 
chelation control in species which do poses electron rich centers. Using these 
three models, chemical reactions can be optimized to produce a product in high 
enantiomer excess.
1.9 Liquid Phase Peptide Synthesis
Liquid phase peptide synthesis (LPPS) is the original approach to peptide 
synthesis. The growing peptide chain is assembled through a lengthy series of 
coupling and purification steps. Some major drawbacks of LPPS are the difficult
17
purification of the intermediate products and the length of time required for the 
synthesis. A major development in peptide synthesis removed the difficult 
purification by synthesizing peptide chains on insoluble resins.
1.10 Solid Phase Peptide Synthesis
Solid phase peptide synthesis (SPPS) was first developed in 1963 by 
Robert Merrifield [60] and was a solution to the inconvenient purification between 
coupling steps in LPPS. The growing peptide chain is linked via a chemical linker 
to an insoluble solid support resin. The resin can be rinsed between coupling 
steps, removing all unwanted elements of the synthesis, without the concern for 
loss of product. Synthesis of the peptide proceeds in the C-terminal to N- 
terminal direction through the use of protected amino acids. There are two main 
strategies available for SPPS: Boc and Fmoc. Both strategies use orthogonal 
cleavage steps, where the N-terminus protecting group can be removed without 
cleaving the resin-peptide linkage or the functional group protectors. In t- 
butyloxycarbonyl (Boc) chemistry the Boc N-protected residues are deprotected 
by neat trifluoroacetic acid (TFA) and the side chain protecting groups and the 
resin linker/peptide bond can be cleaved using concentrated HF. 9- 
fluorenylmethyloxycarbonyl (Fmoc) is removed using 20% piperidine in DMF and 
TFA removes the peptide from the resin and cleaves off the side chain protective 
groups. Due to the use of extremely hazardous HF in the BOC strategy, Fmoc 
chemistry is now generally preferred. Each residue addition cycle requires a
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deprotection of the N-protected group on the growing chain and addition of a N- 
protected residue using hydroxybenzotriazole (HOBT), 2-(1 H-benzotriazole-1- 
yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) and 
diisopropylethylamine (DIPEA). The type of resin linker used determines the 
properties of the cleaved product. For example, using PAL resin (5-(4-Fmoc- 
aminomethyl-3,5-dimethoxyphenoxy)-valeric acid-MBHA) as the solid support 
leaves the peptide C-terminal end amidated upon cleavage, whereas using 
Wang resin renders the C-terminal as a free carboxylic acid. Scheme 1.2 
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1.11 Phosphorylation of Synthesized Peptides
In peptide synthesis there are two phosphorylation strategies available: 1) 
using protected, phosphorylated amino acids as a building block during the 
peptide synthesis and 2) the “global phosphorylation” method where all free
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unprotected hydroxyls available are phosphorylated upon completion of the 
peptide. Global phosphorylation requires the use of unprotected hydroxyl groups 
on the residues which are intended to be phosphorylated. Global phosphorylation 
is generally carried out using phosphoramidite class reagents such as N- 
diisopropylphosphoramidite or N-dibenzoylphosphoramidite in the presence of 
tetrazole to add phosphite ether to free hydroxyls. This is subsequently oxidized 
to a phosophotriester using H2O2 or mCPBA. The phosphate protecting groups 
can then be removed using a strong acid such as TFA, which is convenient for 
Fmoc SPPS as TFA will also cleave the protecting groups from other residues, 
as well decouple the synthesized peptide from the solid support. Scheme 1.3 




1.12 Chymotrypsin Coupled Kinetic Assay
Inhibitors can be assayed using a convenient photometric assay developed 
by Fischer et al. [61], see Figure 1.8. Chymotrypsin hydrolyses the 
phenylalanine-pNA amide linkage of the substrate suc-AEPF-pNA. This action 
releases free pNA into solution which is then detectable by UVA/IS absorption. 
The assay relies on the selectivity of chymotrypsin; chymotrypsin will only cleave 
the pNA from the substrate peptide when the E-P bond of the substrate is in the 
trans conformation (Figure 1.9).
After the initial burst phase of hydrolysis, the assay is allowed to proceed to 
ensure that all remaining substrate in solution is in the cis conformation. 
However, there is a small amount of peptide that is converted to the trans
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conformation thermally in solution. This background chemical conversion rate 
must be subtracted from the observed isomerization rate to give the Pin 1 
isomerization rate. Pin1 is added to the cuvette and as Pin1 isomerizes the 
substrate to the trans conformation it is cleaved by Chymotrypsin to release pNA 
which is then detectable. As Chymotrypsin is in excess it is assumed that the 
release of pNA is dependent on the rate of Pin 1 isomerization.
Inhibitor
Chym otrypsin
S u c-A E P F -p N A[ Trans +  Cis]I /
pN A I C hym otrypsin
P in i Vis Abs




Figure 1.8 Schematic representation of the Chymotrypsin coupled kinetic assay 
developed by Fischer et al. [58]
Figure 1.9 A) peptide substrate suc-AEPF-pNA in the non-cleavable cis conformation 
and B) peptide substrate suc-AEPF-pNA in the cleavable trans conformation
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To determine the effectiveness of the inhibitors, the different inhibitors are 
added to the assay cuvette along with the substrate. Curves generated in the 
presence of inhibitor are compared to those generated in the absence of an 
inhibitor. Though the concentration of substrate varies with each individual trial, 
the concentration of Pin1 and the inhibitor remain constant throughout all trials.
The initial amount of substrate in the cis conformation is a major drawback of 
the assay. In aqueous solution it was found that 90% of the peptide exists in 
trans conformation and thus only 10% of the available peptide could be used for 
the determination of rate of isomerization. In 1991 the assay was improved upon 
by Kofron et al [62]. Lower temperatures were introduced to reduce proteolytic 
cleavage of Pin1 and chymotrypsin as well as to reduce the rate of thermal 
conversion. Multiple wavelengths for absorbance measurements were also 
added to detect cleavage products at higher concentrations. Finally a novel 
solvent system of 50 mM HEPES, 0.1 M NaCI, and 5 mM NaN3 was introduced 
which increases the available percentage of peptide in the cis conformation from 
10:90 cis.trans to a reported 50:50 cis:trans ratio. The increase of peptide in the 
cis conformation increases the confidence these changes to the assay allow for a 
more accurate and efficient testing of Pin 1 isomerase activity.
1.13 Thesis Overview
Throughout the literature, long peptide chains dominate as the preferred 
type of inhibitor for Pin1. These peptide chains exploit binding in the active site 
via the recognition sequence, as well as binding to sites on the periphery of the
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active site. Designing competitive small molecule inhibitors presents a different 
challenge as the binding energy must be from a small area directly around the 
active site of the target protein. Previous research in this lab has shown that the 
substitution of pSer/pThr with (B-phosphorylated glutamic acid increased binding 
to Pin 1. This discovery opened doors for a new class of small molecule inhibitors 
for Pin 1. Whereas previous inhibitors focused on modifying the proline position of 
the recognition sequence and residues removed from the active site. This new 
inhibitor focuses on increased binding through the modification of the pSer/pThr 
position.
Creating a small peptide inhibitor has advantages over the longer chain and 
highly hydrophobic peptides. The advantages include the diminished potential for 
non-selective interactions, the smaller inhibitor can potentially be altered with 
more ease than the larger chains, smaller molecules have the potential to require 
less time to synthesize, and synthesis of smaller molecules has the potential to 
be more cost effective. With all these potential advantages there is a higher 
chance that therapeutic or research-based use would increase.
The main goal of this research was to use rational design to synthesize novel 
inhibitors for Pin1. Using previous findings rational design was used to select 
proline analogues for substitution into Cbz-/_-Glu(P-phos)-Pro-NH2. The 
substitutions were then assessed for inhibitory potential against Pin1 activity. 
Centering the research on the novel p-phosphorylated inhibition strategy, we 
sought to increase the binding potential through utilizing the strategy of 
substitution at the proline position. It was thought that testing both successful
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proline mimics in Pin 1 inhibition studies, such as pipecolic acid, and novel proline 
substitutions, such as morpholine and methylpiperazine - both chosen in a 
rational design fashion, would render a strong, easily synthesized, inhibitor of 
Pin 1.
Another goal was to increase the product yield of the Reformatsky addition in 
this application as low yields are unfavourable for a multi step synthesis.
This thesis will demonstrate the successful screening of four different C- 
terminal moieties coupled to p-phosphorylated glutamic acid, all of which are 
novel to Pin1 inhibition studies.
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Chapter Two: Results & Discussion
2.1 Synthesis of N, C Protected Serine Aldehyde
Previous work in this lab determined that Cbz-Glu((3-phos)-Pro-NH2 was 
active against Pin1 isomerase activity (Kj = 20.0+0.9 pM). It was hypothesized 
that the magnitude of inhibition could be increased through substituting the 
proline with structural analogs through stronger interaction with the active site of 
Pin1. To test this hypothesis four novel dipeptides, which are based on the p- 
hydroxyl substituted glutamic acid core molecule, were synthesized.
In 1993 Blaskovich and Lajoie [1] published a novel methodology for the 
synthesis of non-proteinaceous, p-substituted a-amino acids. The method utilized 
an OBO ester (4-methyl-2, 6, 7-trioxabicyclo[2.2.2]octane ester) as the carboxyl 
group protector. The OBO ester provides 1) protection from racemization at the 
a-carbon through reduction of a-hydrogen acidity, and 2) aids in the 
stereoselective addition to the p-carbon. The p aldehyde of serine is an excellent 
intermediate as it allows for the addition to the p-carbon using different strategies 
such as the Reformatsky reaction or Grignard reaction.
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Scheme 2.1
The starting material, oxetane tosylate, 1, was prepared on large scale, 20 
g, with high yield (78%) through the addition of 3-methyl-3- 
(hydroxymethyl)oxetane to p-toluenesulfonyl chloride in the presence of pyridine. 
Cbz-serine oxetane ester, 2, was then synthesized through the addition of 1 to 
Cbz-Ser through the formation of a cesium salt, catalyzed by the presence of the 
iodide ion (78%). To complete the protection of the carboxylic acid, the oxetane 
ester, 2, was rearranged to the OBO ester using BF3 as a Lewis acid catalyst
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(81%). The (3-hydroxyl was converted to a (3-aldehyde under Swern oxidation 
conditions (crude yield of 91%). Purification of the aldehyde, 4, through 
chromatography could potentially lead to racemization of the a-carbon through 
enolate formation [1]. Thus, the aldehyde was not purified before further reaction. 
Fortunately, purification is not a great concern for several reasons: 1) the yield of 
a Swern oxidation has been shown to be high [2, 3]; and 2) any alcohol 
remaining will not be reactive towards nucleophiles and will be removed in 
subsequent purification.
2.2 Reformatsky Addition
After the synthesis of 4, alkylation of the aldehyde was carried out using t- 
butyl bromoacetate (tbba) under Reformatsky addition conditions to synthesize 
Cbz-Glu(t-Bu)((3-OH)-OBO, 5. The Reformatsky is much like the Grignard 
reaction but uses Zn metal in place of Mg to add an acetate group to a carbonyl. 
Previous reports presented a yield of 27%; however, the reaction yielded enough 
material to continue with the synthesis to the final product. In that instance only 
one inhibitor was synthesized using the Reformatsky addition and the low yield 
was not investigated. For our purposes ca. 30% yield is a waste of starting 
materials and not synthetically favourable. Initial attempts using the prescribed 
method yielded 33%, which is still too low for a multi-step synthetic process. 
Potential problems could be one, or a combination, of: water contamination; low 
yield of the Swern oxidation; incomplete consumption of the reactants; improper 
ratios of reactants; and zinc purity.
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Water contamination would cause a “quenching” of the reaction, and thus 
could result in low yields. As one of the simplest and most logical problems to 
address, fresh reagents were dried using molecular sieves in septum bottles and 
handled under argon to ensure that moisture in the air was not contaminating the 
reactants. A source of water could also have come from the aldehyde product. 
Cbz-Ser(ald)-OBO, 4, was reconstituted in freshly distilled CH2CI2 and dried over 
MgS04 before the solvent was removed in vacuo and then placed under high 
vacuum. The apparatus for the reaction was improved by using a two-neck round 
bottom flask (RBF) and introducing a stopcock to the second neck under argon 
flow, to allow addition of reactants without exposing the reaction to atmosphere. 
Performing the Reformatsky with carefully dried reagents and new apparatus 
yielded no significant change (34%). Water contamination did not seem to be the 
problem. However, the use of fresh dry reagents is always recommended. Thus, 
the carefully dried reagents and the improved apparatus were used for the 
remaining trials.
The purity of Zn was addressed next. Zn metal was cleaned in 
concentrated HCI to remove any oxide, washed with 50%, 70% and 99% 
EtOH/H20  solutions, rinsed twice with MeOH and dried at 110°C. The 
Reformatsky reaction with purified Zn metal yielded no change (31%). Purified 
Zn was used for the remainder of all subsequent reactions.
The Swern oxidation has been shown to be very effective and result in a 
high yield in different applications [2, 3]. However, having an ineffective oxidation 
process would lead to low yields in the Reformatsky addition. To determine if the
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aldehyde was the cause of the low yield of the Reformatsky reaction the efficacy 
of the oxidation process had to be ascertained. Using TLC as an indicator to 
determine completion was not very effective as the aldehyde tended to streak on 
the plate. High resolution mass spectrometry also indicated that the product Cbz- 
L-Ser(ald)-OBO was synthesized; however, it does not rule out low yield as mass 
spectrometry is not quantitative. Fortunately, with 1H NMR one can directly 
compare the spectra of Cbz-/_-Ser-OBO, 3, and Cbz-Z_-Ser(ald)-OBO, 4. It is 
evident in the Cbz-Z_-Ser(ald)-OBO that the oxidation had been successful 
through the gain of a signal peak at 9.69 ppm, which is indicative of an aldehyde. 
Complementing the gain of an aldehyde peak would be the loss of the hydroxyl 
and the (3-hydrogens signal as well. Both the loss of the hydroxyl peak at 2.51 
ppm as well as the loss of the peak at 2.55 ppm which represented the pair of p- 
hydrogens can be clearly seen. Please refer to Figures 2.1 and 2.2 for 1H NMR 
spectra of Cbz-Z_-Ser-OBO, 3, and Cbz-L-Ser(ald)-OBO, 4, respectively.
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Figure 2.1 400 MHz 1H NMR, CDCI3 , of Cbz-/_-Ser-OBO, 3.
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Figure 2.2 400 MHz 1H NMR, CDCI3, of Cbz-/.-Ser(ald)-OBO, 4.
If the reaction had been of low yield the 1H NMR spectrum of Cbz-L- 
Ser(ald)-OBO would contain peaks belonging to both Cbz-/_-Ser(ald)-OBO as 
well as Cbz-/_-Ser-OBO. As the evidence supports that the oxidation was 
successful it was thought that the methodology of the Reformatsky addition was 
faulty. A survey of the literature revealed that different methods (including 
different reagents) were used to achieve Reformatsky additions with higher yields36
[4-7], Many of these reactions were performed over longer periods of time than 
what this lab was performing. Some were at room temperature or at reflux. 
Without changing the reagents in the synthetic process which was already 
developed, attempts were made to increase the yield by changing the addition 
order of the reactants as well as changing the length of different reaction stages. 
These changes are summarized in Table 2.1.
As Table 2.1 demonstrates many of the changes in methodology show 
little to no change in yield, and in some cases lowered yields. However, in trial 27 
the quantities of all the reactants were doubled, except for the aldehyde, 4, to 10 
equ and the reaction was carried out. This reaction yielded 64% of expected 
product upon purification and crystallization. However, it was unclear if the 
increase in yield was due to the change in the reagent quantities or the change in 
workup extractions that were required. Upon quenching the reaction and during 
separation in the workup, it was noticed that there was a significant increase in 
the volume of the emulsion layer between the aqueous and ethereal phases. 
This layer of insoluble material was not unexpected, as it was present in all 
previous workups. However, the increased amount of material proved to be a 
challenge in easily separating the layers. As a result more extraction steps with 
CH2CI2 were required to properly separate the two layers. With the increased 
volume of insoluble matter it was noticeable that during each subsequent 
extraction step the emulsion became whiter and less ‘fluffy’. This change was not 
immediately apparent in the smaller quantities.
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1-3 Zn (5 equ), Iodine (cat)
reflux for 10 
mins
tbba (5 equ), 
Aldehyde (1 equ) 20:30 28-30
4-6 Zn (5 equ), Iodine (cat)
reflux for 10 
mins
tbba (5 equ), 
Aldehyde (1 equ) 40:30 19-25
7-10 Zn (5 equ), Iodine (cat)
reflux for 10 
mins
tbba (5 equ), 
Aldehyde (1 equ) 60:40................................... 21-26
11 Zn (5 equ), Iodine (cat), tbba (5 equ)
.........................................
reflux for 10 
mins Aldehyde (1 equ) 20:30 27
12-15 Zn (5 equ), Iodine (cat), tbba (5 equ)
reflux for 20 
mins Aldehyde (1 equ) 40:30 29-32
16,17 Zn (5 equ), Iodine (cat), tbba (5 equ)
reflux for 20 
mins Aldehyde (1 equ) 60:30 22-36
18,19 Zn (5 equ), Iodine (cat), tbba (5 equ)
reflux for 20 
mins Aldehyde (1 equ) 60:60 27-31
20
Zn (5 equ), Iodine 
(cat), Aldehyde (1 
equ)
reflux for 10 
mins tbba (5 equ) 20:30 14
21-24 Zn (5 equ), Iodine (cat), tbba (5 equ)
heated Zn 





Aldehyde (1 equ) 20:30 31-32
25,26 Zn (6 equ), Iodine (cat), tbba (6 equ)
heated Zn 





Aldehyde (1 equ) 40:30 30-35
Tab e 2.1 Continued on next page
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27*
Zn (10 equ), 
Iodine (cat), tbba 
(10 equ)
heated Zn 





Aldehyde (1 equ) 40:60 64
28*
Zn (5 equ), Iodine 
(cat) reflux for 10 mins
Aldehyde (1 equ) 
tbba (5 equ) 20:30 58
29* Zn (5 equ), Iodine (cat), tbba (5 equ)
heated Zn 





Aldehyde (1 equ) 20:30 56-67
Table 2.1 Summary of methods attempted. The * denotes trials which were 
performed with additional washing steps.
To verify, the reaction was performed using the original five equivalents of 
reactants but the workup was altered to include extra extraction steps using 
CH2CI2 (trial 28). Again, it was noticed that upon each wash the emulsion 
became whiter and less expanded. Part-way through the separation, the 
precipitate was collected from the separatory funnel, rinsed with CH2CI2 and the 
fraction was spotted on TLC plate and verified by MS. It was found that product, 
Cbz-Glu(t-butyl)(p-OH)-OBO, 5, was indeed still present in the insoluble/emulsion 
layer. Changing the workup to include more extractions with CH2CI2 yielded a 
maximum 68% product upon purification and crystallization.
It was found that the method used for trials 21-24 was the simplest to 
perform and the easiest to control. Separating the additions of the reactants, t- 
butyl bromoacetate and the aldehyde, lead to less unreacted Zn metal remaining 
in the reaction vessel after completion of the reaction. This change also allowed
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for quicker additions of the reactants to the reaction vessel minimizing exposure 
to atmosphere.
The stereochemical selectivity for this particular example can be directly 
explained using Cram’s model, the Felkin-Anh model as well as 1,2 chelation 
control. Figure 2.3 demonstrates the Cram conformation (Figure 2.3 - A), the 
most probable conformation using the Felkin-Anh model (Figure 2.3 - B), and 
possible conformations using a 1,2 chelation control mechanism (Figure 2.3 -  C 
and D). The use of the highly coordinating Zn metal, the configuration of the 
preexisting stereocenter of the a-carbon, the steric bulk of the OBO ester, and 
the existence of a free electron pair on the amide nitrogen all provide excellent 
conditions for 1,2 chelation control. Both possible configurations of 1,2 chelation 
control render the same stereocenter in the product (Figure 2.3 - E). In addition, 




Figure 2.3 Newman projections showing addition to Cbz-Ser(ald)-OBO using A) Cram’s 
rule, B) most probable addition using the Felkin-Anh model, C/D) possible conformations 
of addition using a 1,2 chelation control mechanism E) Newman projection of the major 
product formed, 5. Where R is the Cbz protecting group.
2.3 Synthesis of Cbz-Glu(t-butyl)(P-OH)-OH
Selective removal of the OBO ester from 5 was carried out by hydrolyzing 
the OBO ester to the 2-methyl-2-hydroxymethyl-1,3-propanediol (MPHD) ester 
(not separated) and then selectively removing the MHPD ester over the t-butyl 
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Purification of the free acid was found to be extremely difficult using 
previously reported methods (unpublished). It was found that purification using 
acetone as the eluent for chromatography was extremely difficult and recovery of 
product was extremely low. Using EtOAc as the eluent in a silica gel column was 
sufficient to separate the product from unwanted materials before crystallization 
(78-96%). 42
Several proline analogues were chosen to be tested for inhibition activity. 
The most obvious candidate for substitution was pipecolic acid. Pipecolic acid is 
chemically similar to proline except that it has a six member ring opposed to 
proline’s five member ring. Pipecolic acid has been shown in a variety of 
examples as an effective proline substitution in Pin 1 inhibition studies [8-12].
Other structures such as morpholine, methylpiperazine, cyclohexylamine, 
and aniline were also selected to act as proline analogues. All of these structures 
are novel to prolylisomerase inhibition studies. As six member rings these 
structures could possibly share the same properties as proline or pipecolic acid, 
as well as introduce different electronic interactions through any heteroatoms 
present in the ring structures. Cyclohexylamine and aniline are not heterocycles 
and have the amide nitrogen removed from the ring structure. This change could 
help assess if the Pin1 recognition sequence will allow for better binding of ring 
structures not bound to the amide nitrogen directly.
The dipeptide Pip-NAL was also chosen for substitution, due to the high 
degree of success Zhang et al [8] had in developing peptide chain inhibitors 
crystals. The Pip-NAL core resolved in crystallographic data showed that the 
naphthyl side chain interacted with an accessory hydrophobic binding pocket 
adjacent to the proline binding pocket in the Pin 1 active site. The choice to use 
this core was to demonstrate the effectiveness of the naphthylalanine binding 
and showcase the novel p-substituted inhibitor design. Figure 2.4 demonstrates 
the different C-terminal structures
2.4 Selection of Pin1 Inhibitor Analogues
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2.5 Synthesis of Pini Inhibitors
2.5.1 Solid Phase Preparation
Both pipecolic acid and NAL have terminal carboxylic acid functionality 
which allows for the convenient use of solid phase peptide synthesis.
2.5.1.1 Synthesis of Cbz-Glu(P-phos)-Pip-NH2
N-protected pipecolic acid was coupled to the PAL solid support resin. 
Fmoc was removed from the pipecolic acid N-terminal and Cbz-Glu(t-butyl)(p- 
OH)-OH was coupled to the pipecolic acid. Both coupling steps utilized classical 
Fmoc chemistry reagents to couple the free N-terminal to the free C-terminal. 
The free hydroxyl was subsequently phosphorylated and oxidized using 
phosphoramidite class reagents. The dipeptide was cleaved from the resin and 
purified using HPLC yielding 5.8 mg of Cbz-Glu(p-phos)-Pip-NH2, 17.
2.5.1.2 Attempted Synthesis of Cbz-Glu(P-phos)-Pip-NAL-NH2
Unfortunately the tripeptide, Cbz-Glu(P-phos)-Pip-NAL-NH2, was not 
successfully synthesized. Using the same methods as synthesis of Cbz-Glu(p- 
phos)-Pip-NH2, N-protected NAL was coupled to the PAL solid support resin. 
Fmoc was then removed from the NAL N-terminal and N-protected pipecolic acid 
was coupled to the NAL N-terminal. Fmoc was removed from pipecolic acid and 
Cbz-Glu(t-butyl)(P-OH)-OH was coupled to the growing chain. The free hydroxyl
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was subsequently phosphorylated and oxidized using phosphoramidite class 
reagents and H20 2 (mefa-chloroperoxybenzoic acid (mCPBA) was initially used 
as an oxidizer. However, upon resin cleavage the process did not yield any 
product. The product was then cleaved from the resin, but the first attempt at 
synthesis failed to yield any detectable product. At each coupling step a 
verification of addition is completed by taking a small sample of the resin from the 
reaction vessel and performing a “mini-cleavage” of that resin. The products of 
the mini-cleavage are checked with mass spectrometry to detect the change in 
the peptide mass. The evidence suggested a loss of product occurred in the final 
steps of phosphorylation and oxidation. It was assumed that human error was the 
cause of the loss, most likely through an error in addition of the oxidizing agent 
mCPBA. The addition of too much oxidizer could cause premature cleavage off 
of the resin leading to a loss of product in the washing of the resin. Proceeding 
with the second attempt mCPBA was substituted with H20 2, which had proved 
successful for the synthesis of both Cbz-/_-Glu((3-phos)-Pip-NH2, 17, and Cbz-/_- 
Glu((3-phos)-Pro-NH2. After several unsuccessful attempts, it was surmised that 
during the oxidation of the phosphite ether or during the cleavage from the resin, 
a side reaction was causing a decomposition of the product as there was no 
detectable product or intermediate in any wash waste or final cleavage.
2.5.2 Liquid Phase Preparation
Morpholine, methylpiperazine, cyclohexylamine, and aniline do not allow 
for the use of SPPS because there is no carboxylic acid functionality, or more
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specifically, any other linkable and cleavable functionalities available for a solid 
phase synthesis resin. Thus, SPPS is not an option and liquid phase coupling 
must be used. Peptide coupling was completed by using 1 equ of Cbz-Z_-Glu(t- 
butyl)(P-OH)-OH, 1 equ HBTU, 1 equ DIPEA and 1.2 equ of a selected proline 
analogue. After coupling, the coupling reagents were removed using a very short 
silica column. The eluent was checked for coupled product, much like the mini­
cleavage process in SPPS, and phosphorylation was completed using 
phosphoramidite class reagents. The protecting groups were then removed using 
TFA and products were purified using reverse phase HPLC. This process was 
done in a fashion similar to solid phase synthesis; intermediate products were 









7, R = Morpholine
8, R = Cyclohexylamine
9, R = N-methylpiperazine
/
11, R = Morpholine
12, R = Cyclohexylamine
13, R = N-methylpiperazine
98%TFA, 1% TIPS, 1%H20
14, R = Morpholine = 66%
15, R = Cyclohexylamine = 59%
16, R = N-methylpiperazine = 63%
The aromatic ring aniline failed to couple with success, even after 72 
hours of continuous reaction. Checking the reaction status by MS indicated that 
the starting products were still present in the solution. The reason for the 
incomplete reaction can be explained by the aromaticity of the aniline ring 
diminishing the nucleophilicity of the amine. The delocalization of the charge
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allows for several resonance structures which have a full positive charge on the 
nitrogen, preventing addition to a carboxylic acid (see Figure 2.4).
The distribution of charge around the aromatic ring can be reduced 
through the substitution of hydrogen with electron rich groups at the ortho and/or 
para positions of aniline. For example, the use of 2-methoxyaniline, as a proline 
analogue could prove effective in coupling to Cbz-/_-Glu(t-butyl)(p-OFI)-OH. The 
methoxy group at the ortho position would increase the nucleophilicity of the 
nitrogen through electrostatic repulsion of electron density at the ortho position.
Figure 2.4 Visualization of electron delocalization in aniline.
Any alternate pursuits to couple aniline to Cbz-/_-Glu(t-butyl)((3-OFI)-OFI 
were not made. Also, as the idea to utilize substituted aniline, regrettably, was 
generated at the time of writing, no attempts were made to couple Cbz-/_-Glu(t- 
butyl)(p-OH)-OH to any aniline analogue.
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To test the inhibition potential of the synthesized molecules the 
chymotrypsin coupled photometric assay developed by Fischer et al. [13] and 
improved upon by Kofron et al. [14] was used.
The photospectrometer was equilibrated at 0°C. Pin1 substrate, suc- 
AEPF-pNA, was then added to the cuvette. After obtaining a baseline reading, 
chymotrypsin was then quickly added to the cuvette. As the substrate is a 
mixture of both the cis and trans conformations in solution, any substrate in the 
trans conformation was cleaved leaving only peptide in the cis form. During the 
assay there was a small percentage of substrate which was converted to the 
trans conformation thermally and cleaved by chymotrypsin. This is called the 
background chemical conversion rate. This can be calculated by measuring the 
change in absorbance over time after the initial burst of chymotrypsin cleavage 
and before the addition of Pin1. The background chemical conversion rate needs 
to be subtracted from the rate of Pin1 isomerization observed.
Pin 1 was quickly added to the cuvette and the reaction was allowed to go 
to completion. The slope of the initial part of the curve was used to calculate the 
rate of Pin1 isomerization. (Please see Figure 2.5 for a visual representation of 
the tangents used to determine the rate of isomerization and the background 
chemical conversion rate.) Tangent slopes were determined by visual detection 
of the most linear portion of the curve and linear regression was used to ensure 
quality of the fit.
2.6 Pin1 Inhibitor Activity
49
To determine the rate of isomerization the concentration of peptide in the 
cis conformation at the time of addition of Pin1 must be known. Because the 
concentration of free pNA in solution is dependent on the concentration of 
peptide which is cleaved, the concentrations of total peptide as well as the 
concentration of peptide in the cis conformation can be determined using Beer’s 
law. The concentration of peptide in the cis conformation can be calculated by 
using the difference between the absorbance of just prior to the addition of Pin1 
and the absorbance upon completion of the assay. To ensure that pNA cleavage 
is not the rate limiting step of the assay chymotrypsin is added in excess.
Once the rate of background chemical conversion and the initial rate of 
isomerization were calculated the data was plotted on a Michaelis-Menten plot. 




Figure 2.5 Sample raw data of Chymotrypsin coupled Pin 1 enzymatic assays. A) 
Representation of assay without inhibitor present. B) Assay in presence of Cbz-/_-Glu(ß- 
phos)-methylpiperazine. i represents time point where Chymotrypsin is added, ii 
represents time point where Pin 1 is added, iii represents the tangent line of the 
background chemical conversion rate, and iv represents the tangent line of the initial rate 
of Pin1 isomerization.
Substrate was added in increasing quantity to the cuvette to increase the 
concentration of available substrate in cis conformation. The amount of peptide in 
the cis conformation can never be duplicated exactly throughout runs as the 
concentration of cis peptide depends on many factors, such as, 1 ) the thermal 
conversion rate, 2) time between the addition of substrate and Pin1, and 3) the
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amount of peptide in the cis conformation of the stock solution. For example, 
Figure 2.5 A and B are both examples of actual fluorescent data collected with 
the initial addition of the same concentration of total substrate. A) Represents 
data collected with the concentration of cis peptide determined to be 452 pM in 
the absence of an inhibitor and B) represents data collected with cis peptide at 
395 pM in the presence of Cbz-/_-Glu(p-phos)-methylpiperazine. The slope of the 
tangent lines ii and iv indicate the rate of background chemical conversion rate 
(iii) and the rate of initial isomerization of Pin1 (iv).
The results of the chymotrypsin coupled inhibition assays are presented in 
Table 2.2, along with a Michaelis-Menten plot of the different active inhibitors 
(Figure 2.6).
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Table 2.2 Summary of Pini inhibition assays.
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Michaelis-Menten Plot of Pini Chymotrypsin 
Coupled Kinetic Assay Results




Figure 2.6 Pin 1 inhibition Michaelis-Menten plot of synthesized inhibitors which 
demonstrated inhibition activity (n=1 ).
In previous work it was observed that Cbz-Glu((3-phos)-Pro-NH2 exhibited 
a K, = 20.0 + 0.9 pM, here a Kj = 54.1+1.8 pM is determined. The difference in 
the value is most likely due to the use of different Pin1 stocks and isoforms. The 
chymotrypsin coupled kinetic assay was performed using the same procedure 
aside from the use of full length Pin1. In the previous study only the catalytic 
PPIase domain of Pin1 was used for the assay. Because the VWV domain also 
binds to proline containing ligands, the full length enzyme would bind more 
inhibitor as well as substrate than just the single domain. These differences can
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help account for the difference in Kj between the previously reported value and 
the value reported here for Cbz-/_-Glu((3-phos)-Pro-NH2.
The spacious and positively charged phosphate binding cavity in Pin1 
could accommodate movement of the phosphate during Pin1 catalyzed 
isomerization of the Pro-pSer/pThr bond [8 ]. If that is indeed true the modified 
serine containing a negatively charged acetyl group could help to inhibit the 
action in two ways: 1 ) by filling up a cavity adjacent to the phosphate moiety 
making any “rolling” difficult; and 2 ) by possibly creating a salt bridge or hydrogen 
bond with Arg6 8 , causing binding to Pin1 to become more energetically 
favourable. The substitution of proline with analogues should not directly affect 
the binding of the phosphate or the postulated interaction between Pin1 and the 
negatively charged carboxylic acid.
Analysis of the proline binding pocket of Pin 1 structure published by 
Zhang et al. [8 ] (Figure 2.7), shows that there exists more room in the binding 
pocket opposite of the hydrophobic residues, towards His59 and His157. The 
“greasy” binding pocket formed by Leu122, Met130, and Phe134 allows for 
stronger hydrophobic interaction between the inhibitor and the enzyme.
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Figure 2.7 NMR structure of the binding pocket of Pin1. Bound to Pin 1 is the 
peptide Ac-Phe-D-Thr(P03 )-Pip-NAL-Gln-NH2 (Thr(P03 )-Pip-NAL-Gln shown) 
adapted from Zheng et al. [8 ].
Substituting proline for pipecolic acid increases the available surface area 
of the inhibitor and does not change the chemical properties substantially. The 
larger group could bind with higher affinity through more interaction with the 
enzyme. This substitution yields only a moderate increase in inhibition over - 
Glu(p-phos)-Pro-NH2.
Increased inhibition qualities of Cbz-/_-Glu(P-phos)-methylpiperazine can 
be explained by: the increase in the available surface area for binding; the 
heterocyclic ring potentially allowing for hydrogen bonding between His157 
and/or His59 and; the methyl group on the amine nitrogen could potentially 
protrude into the gap, towards Phe134, increasing interaction between the 
inhibitor and Pin 1.
Both Cbz-Glu(p-phos)-morpholine and Cbz-Glu(p-phos)-cyclohexylamine 
do not show any inhibitory characteristics. Cbz-Glu(p-phos)-cyclohexylamine 
may not exhibit inhibition qualities due to the extra bond length between the ring56
structure and the amide link as the nitrogen is not part of the cyclic structure as it 
is in proline. This added length may cause too much of an unfavourable 
difference in the structure to be recognized by the selective Pin 1 recognition 
sequence, causing little to no binding of the molecule to Pin1. What is interesting 
is that Cbz-Glu((3-phos)-morpholine also showed no inhibition for PPIase activity. 
It was thought that the inclusion of morpholine would 1) be favourable for 
solubility in vivo, as well as 2 ) increase binding through hydrogen bonding 
potential with the dual histidines in the Pin1 binding pocket. If Cbz-Glu(p-phos)- 
morpholine is compared with Cbz-Glu((3-phos)-methylpiperazine it can be noticed 
that there is a high degree of similarity between the two structures. It is possible 
that the cyclic ether is not hydrophobic enough to cause sufficient binding to the 
greasy binding pocket, but perhaps the methyl group on Cbz-Glu(p-phos)- 
methylpiperazine increases the hydrophobicity of the heterocycle enough to 
allowing for binding.
Cbz-Glu(p-phos)-Pro-NH2, Cbz-Glu(p-phos)-Pip-NH2 and Cbz-Glu(p- 
phos)-methylpiperazine all differ from previously published inhibitors in that no 
inhibitors have utilized the p-carbon of Ser/Thr in the recognition sequence to 
increase binding potential. Either p-phosphorylated glutamic acid or the dipeptide 
Glu(p-phos)-Pip could be used in conjunction with other peptide based designs 
such as those explored by Zhang et al. [8 ], Guo et al. [11], Liu et al. [12], and 
Janowski et al. [15], Duncan et al. [16] very recently published a paper exploring 
the use of non-phosphorylated cyclic peptides as Pin1 inhibitors. It would be of
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interest to test a substitution of Glu((3-phos)-Pip in the cyclic peptide CRYPEVEIC 
at the Y-P position to determine if the peptide exhibited stronger inhibition. 
Although substituting p-phosphorylated glutamic acid would defeat the purpose 
of having a non-phosphorylated peptide, it would be interesting to see if there is 
any change in inhibitory potential if Glu((3-phos)-Pip is substituted into the cyclic 
peptide.
Unfortunately, due to the lack of a linkable group on methylpiperazine, the 
core of Cbz-Glu(p-phos)-methylpiperazine is not compatible with other peptide 
designs or strategies for Pin1 inhibition. However, if 4-Methyl-piperazine-2- 
carboxylic acid were to be used then it would be possible to link into a peptide 
chain. 4-Methyl-piperazine-2-carboxylic acid would contain the same functional 
groups thought to increase inhibition but would give the additional functionality of 
allowing a second peptide bond.
As an example, to compare Cbz-Glu((3-phos)-Pip-NH2 and Cbz-Glu((3- 
phos)-methylpiperazine to compounds such as PiJ and PiB [17] (Figure 2.8) it 
can be easily seen that PiJ and PiB are highly hydrophobic compounds whereas 
Cbz-Glu((3-phos)-Pip-NH2 and Cbz-Glu((3-phos)-methylpiperazine are not. The 
interaction of Pib and PiJ with Pin 1 have been demonstrated using NMR [17], 
however, interactions with other enzymes are highly likely due to non-specific 
binding to hydrophobic surfaces on many different proteins. Also unlike PiB and 
PiJ, Cbz-Glu(|3-phos)-Pip-NH2 and Cbz-Glu(p-phos)-methylpiperazine are 
designed to be specific to the Pin1 recognition sequence. Hopefully, Cbz-Glu(P-
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phos)-Pip-NH2 and Cbz-Glu((3-phos)-methylpiperazine would have reduced non­
specific interactions as they do not contain large hydrophobic groups.
Figure 2.8 Structural representations of PiB and PiJ
One of the goals of this research was to test several proline analogues for 
stronger inhibition than Cbz-L-Glu(p-phos)-Pro-NH2 (Kj = 54.1+1.8 pM), in the 
hopes of developing a sub pM range inhibitor. Unfortunately, we were unable to 
obtain a sub pM range inhibitor. However, Cbz-/_-Glu((3-phos)-Pip-NH2 (Kj = 
45.4+1.1 pM) and Cbz-/_-Glu(p-phos)-Methylpiperazine (Kj = 22.7+1.4 pM) both 
demonstrated a stronger inhibition of Pin 1 than Cbz-Z_-Glu(p-phos)-Pro-NH2.
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Chapter Three: Experimental Section
3.1 Instrumentation
NMR spectra were collected using acetone-d6 (referenced to 2.05 ppm for 
1H NMR, 29.9 ppm for 13C NMR), CDCI3 (referenced to TMS at 0.00 ppm for 1H 
NMR, to CDCI3 at 77.23 ppm for 13C NMR), or D20  (referenced to 3- 
(trimethylsilyl)propionic-2 ,2 ,3 ,3 -d4 acid at 0.00 ppm for both 1H NMR and 13C 
NMR) on a Varian Mercury 400 MHz spectrometer. For any NMR samples using 
CDCI3 which contained an OBO ester, the CDCI3 was pre-filtered through basic 
alumina to remove any traces of acid to retain product integrity during 
measurement.
Melting points were determined using a Mel-Temp melting temperature 
apparatus using open capillary tubes. Melting temperatures recorded are 
uncalibrated.
Mass spectral (MS) analyses were performed on a Micromass Quattro 
Micro ESI-MS instrument. Accurate mass/elemental analysis was carried out 
using a Varian QFT-12 FT-ICR.
TLC was carried out on EMD Chemicals Inc. aluminum backed silica gel 
60 F254, with visualization of spots by UV or a solution of 2% ninhydrin in MeOH 
and UV. Flash chromatography was performed with silica gel 60 (70-230 mesh) 
from EMD Chemicals Inc.
Semi-preparative HPLC analyses were performed using a Waters 600E 
HPLC system controller with a Waters 600 multisolvent delivery system and
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detection was carried out using a Waters 2487 Dual A absorbance detector. The 
column used was Agilent Zorbax 300SB-C18 (250x9.4mm, 5 pm). Analytical 
HPLC analyses were performed using Agilent 1100 Series HPLC system with a 
Phenomenex Jupiter 5u C18 300A (250x2mm, 5 pm) column coupled with the 
Micromass Quattro Micro ESI-MS to positively identify elution peaks.
3.2 Reagents
Triethylamine, oxalyl chloride, diisopropylethylamine, tetrahydrofuran, 
boron trifluride etherate, pyridine, tert-butyl bromoacetate, ethyl acetate, 
triflu roacetic acid, dibenzyl N,N-diethylphosphoramidite, dimethylsulfoxide, 
morpholine, 1-N-methylpiperazine, 3-methyl-3-oxetanemethanol (oxetane), 
cyclohexylamine, mefa-chlorobenzoic acid, pipecolic acid were purchased form 
Sigma-Aldrich and used without any further purification.
Iodine, dimethylformamide, cesium carbonate, p-toluenesulfonyl chloride 
and sodium iodide were purchased from Caledon Labs and dichloromethane was 
purchased from J.T. Baker.
PAL amide resin was purchased from Advanced Chemtech; Cbz-serine 
and peptide coupling reagents HOBT and HBTU were purchased from 
Novabiochem.
Full Pin 1 enzyme was collected and purified from recombinant E. Coli and 
graciously given by the Shilton lab.
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3.3 Chemical Synthesis
3.3.1 Oxetane Tosylate, 1
3-Methyl-3-(toluenesulfonyloxymethyl)oxetane, Oxetane tosylate, 1. 57.2 g (0.3 
mol) of p-toluenesulfonyl chloride was dissolved in dry pyridine (250 ml_) under 
argon. 3-Methyl-3-(hydroxymethyl)oxetane (20.4 g, 0.2 mol) was added slowly, 
and the solution was stirred for 1.5 h. The mixture was added slowly to a rapidly 
stirring mixture of deionized water (700 ml_) and crushed ice (700 g,) in a 2 L 
Erlenmeyer flask and allowed to stir for an additional 0.5 h. The white precipitate 
was then vacuum filtered on Whatman filter paper # 1 and washed with cold H20. 
The product was dried under high vacuum to obtain the white powder of oxetane 
tosylate (36.8 g, 78%). Mp 48-50°C (lit 49.5-51°C [1]) 1H NMR (CDCI3, 400 MHz) 
5 1.30 (s, 3H), 2.44 (s, 3H), 4.16 (s, 2H), 4.38 (m, 4H), 7.39 (d, 2H), 7.81 (d, 2H). 
High resolution MS calc’d for C i2 Hi60 4SiNa (M+Na+) 279.06615, found 
279.06611 (M+Na+).
3.3.2 Cbz-L-Ser-Oxetane Ester, 2
2-Benzyloxycarbonylamino-3-hydroxypropionic acid 3-methyloxetane-3-ylmethyl 
ester, Cbz-L-Ser-Oxetane ester, 2. 1 (11.36 g, 0.047 mol) and Cs2C 0 3 (9.19 g, 
0.028 mol, 0.6 equ) were combined and dissolved in a 500 mL round bottomed 
flask (RBF) using 100 mL deionized H20. The water was then removed in vacuo, 
and the resulting oil was lyophilized for 12 h yielding white foam. The foam was 
then taken up in DMF (200 mL), oxetane tosylate, 1 (12.65 g, 0.049 mol) and Nal
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(1.41 g, 9.8 mmol, 0.2 equ) were added and allowed to stir under Ar for 48 h. 
The DMF was then removed in vacuo, and the resulting solid was dissolved 
using alternating aliquots of EtOAc (600 ml_ total) and H20  (200 mL total). The 
organic layer was separated and extracted with 10% NaHC03 (2x 100 mL) and 
saturated NaCI (1 * 100 mL), and then dried over MgS04. The solvent was 
removed under reduced pressure to yield a yellow oil which was recrystallized 
from Et20  to yield colorless rod-like crystals in 78% yield (11.9 g). mp 62-64°C (lit 
[2] 58-60°C); [a]20D = -8.2 (c = 0.875, EtOAc) (lit [2]-8.3, c = 1.0, EtOAc); TLC 
(2:1, EtOAc:Hexane), R, = 0.42; 1H NMR (CDCI3, 400 MHz) 61.26 (br s, 3H), 
2.88 (t, 1H), 3.88-3.95 (br m, 1H), 4.07-4.17 (br m, 2H), 4.42-4.58 (br m, 6 H),
5.14 (s, 2H), 5.74 (d, 1H), 7.28-7.40 (br m, 5H). High resolution MS calc’d for 
C1 6H2 iN 0 6Na (M+Na+) 346.12611, found 346.12632 (M+Na+).
3.3.3 Cbz-L-Ser-OBO Ester, 3
[2-Hydroxy-1 -(4-methyl-2,6,7-trioxa-bicyclo[2.2.2]oct-1 -yl)-ethyl]-carbamic acid
benzyl ester, Cbz-/_-Ser-OBO ester, 3. Cbz-/_-Ser-Oxetane ester, 2 (12.14 g, 
36.6 mmol) was dissolved in dry CH2CI2 (450 mL) and cooled to 0 °C under Ar. 
BF3 Et20  (0.23 mL, 1.83 mmol) was diluted in CH2CI2 (5.0 mL) and added to the 
reaction flask. The reaction was allowed to warm to room temperature and was 
checked by TLC. After 6  h, Et3N (1.28 mL, 9.15 mmol) was added and the 
reaction was stirred for an additional 30 min before being concentrated in vacuo 
to a thick clear oil. The crude product was re-dissolved in EtOAc (400 mL), 
washed with 3% NH4CI (2 x 250 mL), 10% NaHC03 (1 x 250 mL) and saturated
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NaCI (1  x 250 mL), dried (MgS04), and evaporated to dryness. The reaction 
yielded faintly yellow thick oil. The oil was crystallized from EtOAc/Hexane to 
give shiny rod-like crystals in 80.5% (9.52 g) yield. [a]20D = -24.3 (c = 1.025, 
EtOAc) (lit [1] -24.8, c = 1.00, EtOAc); mp 105-107°C (lit [1] 103.5-105°C); TLC 
(2:1, EtOAc:Hexane), Rf = 0.42; 1H NMR (CDCI3, 400 MHz) 6 0.82 (s, 3H), 2.51 
(t, 1H), 3.61 (m, 2H), 3.85-3.95 (m, 8 H), 5.12 (m, 2H), 5.30 (d, 1H), 7.25-7.39 (m, 
5H). High resolution MS calc’d for C16H2 iN 0 6Na (M+Na+) 346.12611, found 
346.12608 (M+Na+).
3.3.4 Cbz-L-Ser(ald)-OBO Ester, 4
[1 -(4-Methyl-2,6,7-trioxa-bicyclo[2.2.2]oct-1 -yl)-2-oxo-ethyl]-carbamic acid benzyl 
ester, Cbz-/_-Ser(ald)-OBO Ester, 4. Cbz-L-Ser-OBO Ester, 3, (9.1 g, 28 mmol) 
was dissolved in freshly distilled CH2CI2 (80 mL) under Ar and cooled to -78 °C in 
flask 1 (100 mL RBF). 22.5 mL of oxalyl chloride (2.0 M in DCM, 45 mmol, 1.60 
equ) was added to dry CH2CI2 (100 mL) in a separate 250 mL round-bottom flask 
(flask 2) under Ar and cooled to -78 °C. Dry DMSO (7 mL, 90 mmol, 3.2 equ) 
was added to the oxalyl chloride solution (flask 2 ), and the mixture was stirred at 
-78 °C for 15 min. The solution in flask 1 was transferred slowly by cannula to 
flask 2 over a period of 45 min and then rinsed with dry CH2CI2 (25 mL). The 
resulting cloudy, white mixture was stirred for 1.5 h at -78 °C. DIPEA (24.27 mL, 
0.14 mol, 5 equ) was added and the solution stirred for 30 min at -78 °C and 10 
min at 0 °C. Ice-cold CH2CI2 (250 mL) was added, and the solution was washed
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with ice-cold 3% NH4CI (3 * 250 mL) aqueous 10% NaHC03 (1 x 250 mL) and 
saturated NaCI (1 * 250 mL), dried (MgS04), and evaporated to dryness. The 
product was placed on hi-vacuum for 24 hours to remove any solvent remaining 
to ensure dryness. The reaction yielded a pale yellow solid in 91.3% (7.92 g) 
yield. [a]20D = -78.1 (c = 0.95, EtOAc) (lit [1] -99.3, c = 1.03, EtOAc); TLC (1:1, 
EtOAc:Hexane), Rf = 0.8; 1H NMR (CDCI3, 400 MHz) 5 0.81 (s, 3H), 3.82-3.98 (br 
m, 6 H), 4.61 (d, 1H), 5.04-5.16 (br m, 2H), 5.36 (d, 1H), 7.24-7.40 (br m, 5H), 
9.69 (s, 1H). High resolution MS calc’d for C i6 Hi9 N06Na (M+Na+) 344.11046, 
found 344.11051 (M+Na+).
3.3.5 Cbz-L-Glu(OtBu)(p-OH)-OBO Ester, 5
4-Benzyloxycarbonylamino-3-hydroxy-4-(4-methyl-2,6,7-trioxa-bicyclo[2.2.2]oct- 
1-yl)-butyric acid tert-butyl ester, 5. Zinc powder (100 mesh, 0.500 g, 7.70 mmol, 
5 equ), iodine (2 small crystal), and dry THF (30 mL) were heated to reflux in a 
dry 100-mL flask under Ar. Tert-butyl bromoacetate (1.25 mL, 7.70 mmol, 5 equ) 
was added quickly to the refluxing solution and rinsed with 5 mL THF. Solution 
was allowed to reflux until all Zn had reacted, approx 15 mins. At that point, a 
solution of crude Cbz-Z_-Ser(ald)-OBO Ester, 4, (0.500 g, 1.17 mmol, assuming 
100% yield of the aldehyde from oxidation) in 15 mL of THF was added. The 
solution was refluxed for 2 0  min, allowed to cool to room temperature 
(approximately 30 mins), and then poured into 150 mL of aqueous 5% NH4CI. 
CH2CI2 (1 0 0 mL) was added, and the organic layer was separated, washed with 
5% NH4CI (1 x 150 mL) and saturated NaCI (1 x 150 mL), dried (MgS04), and
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evaporated to dryness yielding clear oil. Purification by flash column 
chromatography (silica gel, 2:1 EtOAc:hexane), and recrystallization gave 0.320 
g (6 8 % yield over two steps) of a white solid, mp 48-51 °C (previous unpublished 
work 48-51 °C); [a]20D = -6.3 (c = 1.00, EtOAc) (previous unpublished work [a]20D 
= -6.2 c = 1.00, EtOAc); TLC (1:1, EtOAc:hexane) Rf = 0.61; 1H NMR (CDCI3, 
400 MHz) 6 0.82 (s, 3H), 1.43 (m, 9H), 2.38-2.50 (m, 2H), 3.03 (s, 1H), 3.82-3.96 
(m, 7H), 4.62 (m, 1H), 5.12 (m, 1H), 5.35 (d, 1H), 7.23-7.38 (m, 5H); High 
resolution MS calc’d for C2 2H31NO8 (M+H+) 438.21224, found 438.21223 (M+H+).
3.3.6 Cbz-L-Glu(OtBu)(P-OH)-OH, 6
2-Benzyloxycarbonylamino-3-hydroxy-pentanedioic acid 5-tert-butyl ester, Cbz-/_- 
Glu(OtBu)((3-OH)-OH, 6. Cbz-/_-Glu(0tBu)((3-0H)-0B0 Ester, 5 (0.15g, 0.34 
mmol) was dissolved in 40 ml_ EtOAc. 4 mL of 5% TFA solution in DCM was 
added and the reaction mixture was stirred for 2 h under Ar. Conversion to 
intermediate product 2-Benzyloxycarbonylamino-3-hydroxy-pentanedioic acid 5- 
tert-butyl ester 1-(3-hydroxy-2-hydroxymethyl-2-methyl-propyl) ester, was 
checked by MS [calc’d for C2 2H33O9 N for 455.50, found 456.26 (MH+)]. The 
reaction mixture was evaporated to oil, and re-dissolved in 40 mL THF. 40 mL of 
LiOH (45mM, 5 equ) was added to the solution, and stirred for 20 h at room 
temperature. The solution was acidified with 0.1N HCI to pH4.0, and extracted 
with EtOAc (3 x 50 mL). The organic layer was dried (MgS04) and evaporated to 
an oil. Purification by flash column chromatography (silica gel, EtOAc) and 
recrystallization (acetone:CH2CI2) yielded colorless crystals (78-96%, 0.96 g -
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0.118 g): mp 58-60 °C; [a]20D = +1.1 (c = 0.52, acetone); TLC (acetone) Rf = 
0.25; 1H NMR (acetone-d6/D20, 400 MHz) 6, 1.42 (s, 9H), 2.38-2.60 (br m, 2H), 
4.38 (b, 1H), 4.63 (b, 1H), 5.01-5.15 (br m, 2H), 7.22-7.42 (br m, 5H); High 
resolution MS calc’d for C17H23 N0 7Li (M+Li+) 360.16291, found 360.16325 
(M+Li+).
3.3.7 General Liquid Phase Peptide Coupling and Phosphorylation
1 equ of Cbz-/_-Glu(OtBu)(p-OH)-OH is dissolved in CH2CI2:DMF (1:1, 40 
mL) along with 0.1 equ HOBt, 0.95 equ HBTU and 1 equ of DIPEA x under 
nitrogen and stirred for 5 min. 1.2 equ of the C-terminal amine was added to the 
reaction vessel and stirred for 24 h. Solvent was removed under strong vacuum 
to produce a yellow mixture of oil and solid. The mixture was brought up in a 
minimum volume of CH2CI2 and purified by flash column chromatography (silica 
gel, CH2CI2).Dibenzyl N,N-diethylphosphoramidite (12 equ) is added to a solution 
of the Cbz N-protected dipeptide in THF (10 mL) under argon in a 50 mL RBF. 
1H-Tetrazole (2.5 equ) is then quickly added to the solution and stirred for 25 min 
at room temperature. The solution is cooled in an acetone/dry ice bath and a 
solution of 85% mCPBA (12 equ) in CH2CI2 is slowly added, the solution is 
removed from the dry ice bath and allowed to stir for 2 0  min at room temperature. 
10 mL of a 10% Na2S20 5 solution is added to the mixture and the aqueous phase 
is separated and discarded. The ethereal phase is washed with 10% Na2S20 5 (1 
x 30 mL), 5% NaHC03 (2 x 30 mL), 5% citric acid (pH 3.3: 1 x 30 mL) and
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backwashed with 5% NaHC0 3  (30 mL), dried with MgS04 and filtered. Solvent 
was removed in vacuo to produce an oil. The product was lyophilized to remove 
any trace water, and the phosphorylation process was repeated once more. The 
product was verified using MS then immediately cleaved.
3.3.8 General Protocol for Cleavage of Protecting Group
50 mL of a 95% TFA/5% H20  solution was added to a 100 mL RBF 
containing the protected phospho-dipeptide and stirred for 4 hours. TFA and H20  
were removed in vacuo and the resulting product was brought up in 50 mL H20  
and 20 mL Et20. The ethereal phase was discarded and the aqueous phase 
washed with Et20  (2 x 20 mL). The solvent was removed in vacuo to ensure 
complete removal of any organic solvent, and lyophilized. The product was 
purified using RP FIPLC (solvent A: hl20, solvent B: Acetonitrile).
3.3.9 Solid Phase Peptide Synthesis
PAL resin (100 mg, 0.05 mmol) was swelled in CH2CI2 (20 mL for 10 min), 
and rinsed with DMF (2 x 20 mL). For every amino acid coupling cycle, the Fmoc 
group was removed using 20% piperidine in DMF (20mL for 2x10 min). After 
washing the reaction vessel carefully with DMF (4 x 20 mL), a solution of amino 
acid (4 equ), HOBt (3.8 equ), HBTU (0.5 equ), and DIPEA (4 equ) in DMF/DCM 
(20 mL) was added to the resin, shaken for 4 h washed, rinsed and repeated.
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3.3.10 Resin Cleavage and Protecting Group Removal
A solution of TFA/H20  (95:5) was used to simultaneously cleave the resin- 
amide bond and remove all protecting groups except the Cbz group. 50 ml_ of 
solution was used and stirred for 6  hours. The solution was filtered to remove 
resin and the solvent was removed in vacuo. The resulting product was brought 
up in 50 ml_ H20  and 30 mL Et20  and the ethereal phase discarded. The 
aqueous phase was washed with Et20  (2 x 30 mL). Solvent was removed in 
vacuo to ensure complete removal of any organic solvent and lyophilized. 
Product was purified using RP HPLC (solvent A: H20, solvent B: Acetonitrile). 
The peptides were then checked by high resolution MS analysis.
Compounds 14 through 17 are categorized by the retention time and MS. 











Cbz-L-Glu(P-phos)- 36.86 95.3 447.11631 : 447.11663
morpholine, 14 0.7157 ppm
Cbz-L-Glu(p-phos)- 33.16 89.7 459.15269 : 459.15271
cyclohexylamine, 15 0.0436 ppm
Cbz-/_-Glu(p-phos)- 18.82 96.4 460.14794 : 460.14802
methylpiperazine, 16 0.1739 ppm
Cbz-L-Glu(P-phos)- 26.77 94.8 510.12480 : 510.12483
Pip-NH2, 17 0.0588 ppm
Table 3.1 Summary results of peptides synthesized.
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3.3.11 Chymotrypsin Coupled Kinetic Assay
Assay buffer contained 50 mM HEPES, 0.1 M NaCI, 5 mM NaN3 and was 
brought to pH 7.4 with NaOH (amount used varied to maintain a consistent end 
volume of 2 ml_ per assay). Chymotrypsin solution (50 mg/mL in 1 mM HCI, 50 
pL per assay) was made fresh in 500 pL quantities and stored at 0°C to ensure 
minimal degradation of chymotrypsin. The Pin1 substrate solution was prepared 
using dry TFE and contained 25 mM of Suc-AEPF-pNA (kcat/Km = 3410 mM' 1 s'1), 
and 0.3M LiCI. Pin1 solution was prepared at 0.125 mg/mL (50 pL per assay; 170 
nM final concentration)
The assay buffer and substrate solution were added to a clean cuvette 
and equilibrated until 0°C was reached. When used, Pin1 inhibitors were added 
directly to the buffer and substrate in the cuvette prior to assay start. Assays 
were performed at 0°C to minimize proteolytic degradation of Pin1 and chemical 
conversion of cis substrate to trans.
Measurement of absorbance was started and chymotrypsin solution was 
added to the cuvette. When absorbance reached a steady state Pin 1 solution 
was added quickly and reaction was allowed to go to completion. Measurements 
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Alterations in the expression levels, in either direction, of human Pin1 can 
have an effect on the development of cancer and other diseases caused by cell 
cycle deregulation, Tau related pathologies, as well as HIV proliferation. The 
phosphorylation dependency that Pin1 exhibits makes it an attractive target for 
specific anti-cancer and anti-HIV drugs. Unfortunately, reduced Pin 1 activity has 
been shown to increase tau related pathologies such as Alzheimer’s disease. 
Being able to control the rate of Pin1 activity in neural tissue may be valuable in 
studying Alzheimer’s disease.
Slight modifications to the work-up of the Reformatsky addition proved to 
increase the yield of the reaction from a reported 27% to 6 8 %.
Substituting the proline in Cbz-/_-Glu(p-phos)-Pro-NH2 with pipecolic acid 
improved the inhibition capabilities from 54.1+1.8 pM to 45.4+1.1 pM, as 
determined using full length Pin 1 in the chymotrypsin-coupled kinetic assay. 
Substituting proline with N-methylpiperazine demonstrated stronger inhibition 
qualities with a Kj of 22.7+1.4 pM.
These small inhibitors have advantages over the larger counter parts 
developed in other research laboratories. While many other inhibitors to date 
exhibit stronger Kj values, much of these have peptide sequences which, 
presumably, interact with Pin1 at sites removed from the active site. The smaller,
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site-specific di- or tripeptides, which act solely at the active site of Pin1, may 
diminish nonspecific binding in vivo.
In summary, we were able to increase the efficiency of the methods used 
to stereospecificly synthesize Cbz-/_-Glu(t-butyl)(p-hydroxy)-OBO, synthesize 
novel Pin 1 inhibitor candidates, screen them for activity using a chymotrypsin- 
coupled enzymatic assay, and discover two stronger acting inhibitors over Cbz-L- 
Glu((3-phos)-Pro-NH2. Unfortunately, discovery of a nanomolar inhibitor was not 
achieved.
4.2 Future Work
The work in this thesis furthers the research work from previous theses 
from this lab. The author suggests that further research be taken to investigate 
the crystal or possibly the NMR structure of Pin 1 bound to the small inhibitor 
Cbz-/_-Glu(p-phos)-Methylpiperazine, 16, and Cbz-L-Glu(p-phos)-Pip-NH2, 17. 
This would provide structural evidence that the negatively charged glutamic acid 
does interact with the positively charged Lys63 or Arg6 8  as postulated. The 
structural information would also provide details on any contact with the deeper 
proline binding pocket in which the dual histidines reside. This information could 
lead to structural based designs of better small inhibitors.
Based on the published structure of the pipecolic acid naphthylalanine 
containing peptide by Zhang et al. this author strongly suggests further work into 
the synthesis of Cbz-Glu(p-phos)-Pip-NAL-NH2, possibly through non-solid 
phase synthesis strategies. The author also suggests that further research into
75
targeting various kinases and phosphatases, which are known to be active in 
cancer proliferation, using the optimized methodology and structure of the Pin1 
inhibitors demonstrated in this thesis.
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